Chongqing Bovax Biopharmaceutical Co., Ltd. (hereafter referred as to "Chongqing Bovax"), as the wholly-owned subsidiary of Shanghai Bovax Biotechnology Co., Ltd., is an innovative enterprise focusing on the R&D and industrialization of recombinant protein vaccines and drugs. It was established in Chongqing BioPark in 2016, and used for the industrialization of prophylactic recombinant protein vaccines.
Chongqing Bovax has mastered the international advanced genetic engineering recombinant Virus-Like Particles technology (VLPs technology), and has established multiple technology platforms with recombinant expression of VLPs in eukaryocyte systems as the core technology. These technology platforms have a wide range of applications in prophylactic vaccines and therapeutic drugs for cancers and infectious diseases, such as human papillomvavirus (HPV) vaccine, hand-foot-and-mouth disease (HFMD) vaccine and Norovirus vaccine. Chongqing Bovax is in a leading position in the field of HPV vaccine research and development in China.  
Chongqing Bovax has more than 10 products in the pipeline , and has obtained 4 clinical approvals. The 4-valent HPV vaccine and the 9-valent HPV vaccine are currently in Phase III clinical stage, while the 15-valent HPV vaccine and EV71 vaccine are in Phase I clinical stage. Among them, the 9-valent HPV vaccine has received support from the Ministry of Science and Technology of China as The Science and Technology Major Project of "Significant New Drugs Development" during "The 13th Five-Year Plan", and it is the first of its kind in China to obtain clinical approval and conduct Phase III clinical trials.
   

Chongqing Bovax is currently focusing on the industrialization construction for recombinant HPV vaccines and other projects, with an investment of over 2 billion RMB. The company has completed the construction of 12 GMP-compliant monovalent bulk automatic production lines with fermentation scales of 500L/1000L, 1 PFS preparation automatic production line and 1 vial preparation automatic production line. Additionally, the construction of quality research center and cold storage have been completed. The annual production capacity for recombinant 9-valent HPV vaccine is 36 million doses, ensuring the commercial production capability of the following products. At the same time, Chongqing Bovax has established the rules and regulations to ensure the quality and safety of vaccines, and obtained the Manufacturing License of Pharmaceuticals from Chongqing Medical Products Administration in April 2019.  
Bovax has established an R&D and industrialization team of more than 200 employees, led by doctors, with employees owning master's and bachelor's degrees in fields related to biological medicine as team core. HPV vaccines and other vaccines have entered the pilot production stage. It is projected that within 3-5 years after commercialization, the annual value will reach billions of RMB. With a focus on technological innovation as the foundation of development, Bovax places emphasis on technology management and talent acquisition to realize innovation-driven company in the field of biological R&D and industrialization, with advanced technology platforms and a competitive edge in the industry.

Chongqing Bovax Working Environment
核心竞争力是人才与技术
核心竞争力是人才与技术